Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Supernus Pharmaceuticals (SUPN) Current Deferred Tax Assets: 2015

Supernus Pharmaceuticals' Current Deferred Tax Assets was N/A to -$200,000 in Q4 2015 from the same period last year, while for Dec 2015 it was -$200,000, marking a year-over-year change of. This contributed to the annual value of -$200,000 for FY2015, which is N/A change from last year.
As of Q4 2015, Supernus Pharmaceuticals' Current Deferred Tax Assets stood at -$200,000.
In the past 5 years, Supernus Pharmaceuticals' Current Deferred Tax Assets registered a high of -$200,000 during Q4 2015, and its lowest value of -$200,000 during Q4 2015.
In the last 1 years, Supernus Pharmaceuticals' Current Deferred Tax Assets had a median value of -$200,000 in 2015 and averaged -$200,000.